The rotational model and microdialysis: Significance for dopamine signalling, clinical studies, and beyond

Progress in Neurobiology

Volumn 90, Issue 2, 2010, Pages 176-189

  Herrera Marschitz, Mario ^a   Arbuthnott, Gordon ^b   Ungerstedt, Urban ^c  

^a UNIVERSITY OF CHILE   (Chile)

^b Okinawa Institute of Science and Technology Promotion Corporation   (Japan)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Amphetamine; Apomorphine; Basal ganglia; Human brain; Intensive care; Microdialysis; Rotational behaviour

Indexed keywords

4 AMINOBUTYRIC ACID; AMINO ACID DERIVATIVE; AMPHETAMINE; ANTIPARKINSON AGENT; CATECHOL METHYLTRANSFERASE INHIBITOR; CHEMOKINE; CYTOKINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE UPTAKE INHIBITOR; FORMALDEHYDE; GLUTAMIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; NEUROPEPTIDE; NEUROTRANSMITTER; NIALAMIDE; NOMIFENSINE; OXIDOPAMINE; PEPTIDE DERIVATIVE; PROTEIN DERIVATIVE; RGS PROTEIN; TOLCAPONE; UNINDEXED DRUG;

BASAL GANGLION; BIOLOGICAL MODEL; BIOLOGICAL MONITORING; BRAIN ISCHEMIA; CELL COMPARTMENTALIZATION; CIRCLING BEHAVIOR; CLINICAL STUDY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DOWN REGULATION; DRUG RESEARCH; DRUG SCREENING; ELECTRON MICROSCOPY; ENERGY METABOLISM; FLUORESCENCE ANALYSIS; GLOBUS PALLIDUS; HUMAN; IMMUNOHISTOCHEMISTRY; MICRODIALYSIS; MOLECULAR CLONING; NERVE CELL LESION; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROANATOMY; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROSURGERY; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; UPREGULATION;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; GENE EXPRESSION REGULATION; HISTORY, 20TH CENTURY; HUMANS; IMMUNOHISTOCHEMISTRY; MICRODIALYSIS; MOTOR ACTIVITY; NEUROCHEMISTRY; OXIDOPAMINE; PARKINSON DISEASE; RATS; RECEPTORS, DOPAMINE; ROTAROD PERFORMANCE TEST; SIGNAL TRANSDUCTION;

EID: 76849092065     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2009.01.005     Document Type: Review

References (166)

1. Adams R.N. In vivo electrochemical recording-a new neurophysiological approach. Trend Neurosci. 1 (1978) 160-163
2. Agnati L.F., Fuxe K., Zoli M., Ozini I., Härfstrand A., Toffano G., and Ferraguti F. A correlation analysis of the regional distribution of central enkephalin and beta-endorphin immunoreactive terminals and of opiate receptors in adult and old male rats. Evidence for the existence of two main types of communication in the central nervous system: the volume transmission and the wiring transmission. Acta Physiol. Scand. 128 (1986) 201-207
3. Andén N.-E., and Stock G. Inhibitory effect of gamma hydroxy butyric acid and gammaamino butyric acid on the dopamine cells in the substantia nigra. Naunyn-Schmiedeberg's Arch. Pharmacol. 279 (1973) 82-92
4. Andén N.-E., Carlsson A., Dahlström A., Fuxe K., Hillarp N.-A., and Larsson K. Demonstration and mapping out of nigro-neostriatal dopamine neurons. Life Sci. 3 (1964) 523-530
5. Andén N.-E., Dalhström A., Fuxe K., and Larsson K. Functional role of the nigro-neostriatal dopamine neurons. Acta Pharmacol. Toxicol. 24 (1966) 264-274
6. Andén N.-E., Rubenson A., Fuxe K., and Hökfelt T. Evidence for dopamine receptor stimulation by apomorphine. J. Pharm. Pharmacol. 19 (1967) 627-629
7. Arbuthnott G.W., and Wickens J. Space, time and dopamine. TINS 30 (2007) 62-69
8. Arner P., Bolinder J., Eliasson A., Lundin A., and Ungerstedt U. Microdialysis of adipose tissue and blood for in vivo lipolysis studies. Am. J. Physiol. 255 (1988) E737-E742
9. Bentivoglio M., and Morelli M. The organization and circuits of mesencephalic dopaminergic neurons and the distribution of dopamine receptors in the brain. In: Björklund A., and Hökfelt T. (Eds). Handbook of Chemical Neuroanatomy: Dopamine vol. 21 (2005), Elsevier BV, Amsterdam 1-107
10. Bouw R., Ederoth P., Lundberg J., Ungerstedt U., Nordström C.H., and Hammarlund-Udenaes M. Increased blood-brain barrier permeability of morphine in a patient with severe brain lesions as determined by microdialysis. Acta Anaesthesiol. Scand. 45 (2001) 390-392
11. Bunzow J.R., Van Tol H.H.M., Grandy D.K., Albert P., Salon A., Christie M.D., Machida C.A., Neve K.A., and Civelli O. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336 (1988) 783-787
12. Butcher S.P., Fairbrother I.S., Kelly J.S., and Arbuthnott G.W. Amphetamine-induced dopamine release in the rat striatum: an in vivo microdialysis study. J. Neurochem. 50 (1988) 346-355
13. Calabresi P., Pisani A., Mercuri N.B., and Bernardi G. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. TINS 19 (1996) 19-24
14. Campbell G.A., Eckardt M.J., and Weight F.F. Dopaminergic mechanisms in subthalamic nucleus of rat: analysis using horseradish peroxidase and microiontophoresis. Brain Res. 333 (1985) 261-270
15. Cannon W.B., and Rosenbleuth A. The Supersensitivity of Denervated Structures (1949), Macmillan, New York
16. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol. Rev. 11 (1959) 490-493
17. Carlsson A., Fuxe K., Hamberger B., and Lindqvist M. Biochemical and histochemical studies on the effects of imipramine-like drugs and (+)-amphetamine on central and peripheral catecholamine neurons. Acta Physiol. Scand. 67 (1966) 481-497
18. Centonze D., Picconi B., Gubellini P., Bernardi G., and Calabresi P. Dopaminergic control of synaptic plasticity in the dorsal striatum. Eur. J. Neurosci. 13 (2001) 1071-1077
19. Chevalier G., Tierry A.M., Shibazaki T., and Feger J. Evidence for a GABAergic inhibitory nigrotectal pathway in the rat. Neurosci. Lett. 21 (1981) 67-70
20. Christensson-Nylander I., Herrera-Marschitz M., Staines W., Hökfelt T., Terenius L., Ungerstedt U., Cuello C., Oertel W.H., and Goldstein M. Striato-nigral dynorphin and substance P pathways in the rat. I. Biochemical and immunohistochemical evidence. Exp. Brain Res. 64 (1986) 169-192
21. Coons A.H. Fluorescent antibody methods. In: Danielli J.F. (Ed). General Cytochemical Methods (1958), Academic Press, New York 399-422
22. Crow T.J., and Arbuthnott G.W. Function of catecholamine-containing neurones in mammalian central nervous system. Nat. New Biol. 238 (1972) 245-246
23. Cuello A.C., and Paxinos G. Evidence for a long leu-enkephalin striatopallidal pathway in rat brain. Nature 271 (1978) 178-180
24. Dahlström A., and Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol. Scand. Suppl. 232 (1964) 1-55
25. Dahlström A., and Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. II. Experimentally induced changes in the intraneuronal amine levels of bulbospinal neuron systems. Acta Physiol. Scand. Suppl. 247 (1965) 1-36
26. Dearry J., Gingrich J.A., Falardeau P., Fremau R.T.J., Bates M.D., and Caron M.G. Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 347 (1990) 72-76
27. Delgado J.M.R., De Feudis F.V., Roth R.H., Ryugo D.K., and Mitruka B.M. Dialytrode for long-term intracerebral perfusion in awake monkeys. Arch. Int. Pharmacodyn. 198 (1972) 9-21
28. 3 receptor in the rat brain. Neuroscience 65 (1995) 731-745
29. DiChiara G., Olianas M., Del Fiaco M., Spano P.F., and Tagliamonte A. Intranigral kainic acid is evidence that nigral non-dopaminergic neurons control posture. Nature 268 (1977) 743-745
30. DiChiara G., Porceddu M.L., Morelli M., Mulas M.L., and Gessa G.L. Evidence for a GABAergic projection from the substantia nigra to the ventromedial thalamus and to the superior colliculus of the rat. Brain Res. 176 (1979) 273-284
31. Ernst A.M. Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats. Psychopharmacology 10 (1967) 316-323
32. Fairbrother I.S., Arbuthnott G.W., Kelly J.S., and Butcher S.P. In vivo mechanisms underlying dopamine release from rat nigrostriatal terminals. I. Studies using Veratrine and Ouabain. J. Neurochem. 54 (1990) 1834-1843
33. Fairbrother I.S., Arbuthnott G.W., Kelly J.S., and Butcher S.P. In vivo mechanisms underlying dopamine release from rat nigrostriatal terminals. II. Studies using potassium and tyramine. J. Neurochem. 54 (1990) 1844-1851
34. Falck B., Hillarp N.-A., Thieme G., and Torp A. Fluorescence of catecholamines and related compounds condensed with formaldehyde. J. Histochem. Cytochem. 10 (1962) 348-354
35. Ferré S., O'Connor W.T., Fuxe K., and Ungerstedt U. The striato-pallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J. Neurosci. 13 (1993) 5402-5406
36. 3H] SCH 23390. Brain Res. 408 (1987) 205-2009
37. 3H]sulpiride. Eur. J. Pharmacol. 138 (1987) 61-68
38. Freund T.F., Powell J.F., and Smith A.D. Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. Neuroscience 13 (1984) 1189-1215
39. Fuxe K., and Ungerstedt U. Histochemical biochemical and functional studies on central monoamine neurons after acute and chronic amphetamine administration. In: Costa E. (Ed). Amphetamine and Related Compounds (1970), Raven Press, New York 257-288
40. Fuxe K., Corrodi H., Hökfelt T., Lidbrink P., and Ungerstedt U. Ergocornine and 2-Br-α-ergocriptine. Evidence for prolonged dopamine receptor stimulation. Med. Biol. 52 (1974) 121-132
41. Gaddum J.H. Push-pull cannulae. J. Physiol. Lond. 155 (1961) 1-2
42. Garcia-Munoz M., Nicolaou N.M., Tulloch I.F., Wright A.K., and Arbuthnott G.W. Feedback loop or output pathway in striato-nigral fibers?. Nature 265 (1977) 363-365
43. Gerfen C.R., and Wilson C.J. The basal ganglia. Chapter II. In: Swanson L.W., Björklund A., and Hökfelt T. (Eds). Handbook of Chemical Neuroanatomy, vol. 12: Integrated Systems of the CNS. Part III (1996), Elsevier Science BV, Amsterdam 371-468
44. Geurts M., Maloteaux J.-M., and Hermans E. Altered expression of regulators of G-protein signalling (RGS) mRNAs in the striatum of rats undergoing dopamine depletion. Biochem. Pharmacol. 66 (2003) 1163-1170
45. Glowinski J. Properties and function of intraneuronal monoamine compartments in central aminergic neurons. In: Iversen L.L., Iversen S., and Snyder S.H. (Eds). Handbook of Psychopharmacology (1974), Plenum Press, New York 139-167
46. Gold S.J., Ni Y.G., Dohlman H.G., and Nestler E.J. Regulators of G-protein signalling (RGS) proteins: region specific expression in nine subtypes in rat brain. J. Neurosci. 17 (1997) 8024-8037
47. Gomez-Urquijo S.M., Hökfelt T., Ubink R., Lubec G., and Herrera-Marschitz M. Neurocircuitries of the basal ganglia studied in organotypic cultures: focus on tyrosine hydroxylase, nitric oxide synthase and neuropeptide immunocytochemistry. Neuroscience 94 (1999) 1133-1151
48. Gustafsson J., Eriksson J., and Marcus C. Glucose metabolism in human adipose tissue studied by 13C-glucose and microdialysis. Scand. J. Clin. Lab. Invest. 67 (2007) 155-164
49. Gähwiler B.H. Organotypic monolayer cultures of nervous tissue. J. Neurosci. Methods 4 (1981) 329-342
50. Haber S.N., Groenewegen H.J., Grove E.A., and Nauta W.J.H. Efferent connections of the ventral pallidum: evidence of a dual striato pallidofugal pathway. J. Comp. Neurol. 235 (1985) 322-335
51. Herrera-Marschitz, M., 1986. Neuropharmacology and functional anatomy of the basal ganglia. Karolinska Institutet-Thesis, Stockholm, pp. 1-79.
52. Herrera-Marschitz M., and Ungerstedt U. Evidence that apomorphine and pergolide induce rotation in rats by different actions on D1 and D2 receptor sites. Eur. J. Pharmacol. 98 (1984) 165-176
53. Herrera-Marschitz M., and Ungerstedt U. Evidence striatal efferents relate to different dopamine receptors. Brain Res. 323 (1984) 269-278
54. Herrera-Marschitz M., and Ungerstedt U. Effect of the dopamine D-1 antagonist SCH 23390 on rotational behaviour induced by apomorphine and pergolide in 6-hydroxy-dopamine denervated rats. Eur. J. Pharmacol. 109 (1985) 349-354
55. Herrera-Marschitz M., Hyttel J., and Ungerstedt U. The dopamine D-1 antagonist SCH 23390 inhibits apomorphine but not pergolide induced rotation. Acta Physiol. Scand. 122 (1984) 427-428
56. Herrera-Marschitz M., Forster C., and Ungerstedt U. Rotational behaviour elicited by intracerebral injections of apomorphine and pergolide in 6-hydroxy-dopamine-lesioned rats. I. Comparisons between systemic and intrastriatal injections. Acta Physiol. Scand. 125 (1985) 519-527
57. Herrera-Marschitz M., Hökfelt T., and Ungerstedt U. A rotational model sensitive to D-1 but not to D-2 dopamine receptor stimulation. Acta Physiol. Scand. Suppl. 124 542 (1985) 181
58. Herrera-Marschitz M., Christensson-Nylander I., Sharp T., Staines W., Reid M., Hökfelt T., Terenius L., and Ungerstedt U. Striato-nigral dynorphin and substance P pathways in the rat. II: Functional analysis. Exp. Brain Res. 64 (1986) 193-207
59. Herrera-Marschitz M., Goiny M., Utsumi H., Ferre S., Håkansson L., Nordberg A., and Ungerstedt U. Effect of unilateral nucleus basalis lesion on cortical and striatal acetylcholine and dopamine release monitored in vivo with microdialysis. Neurosci. Lett. 110 (1990) 172-179
60. Herrera-Marschitz M., Utsumi H., and Ungerstedt U. Scoliosis in rats with experimentally-induced hemiparkinsonism: dependence upon striatal dopamine denervation. J. Neurol. Neurosurg. Psychiatry 53 (1990) 39-43
61. Herrera-Marschitz M., Meana J.J., Hökfelt T., You Z.-B., Morino P., Brodin E., and Ungerstedt U. Cholecystokinin is released from crossed corticostriatal pathway. NeuroReport 3 (1992) 905-908
62. Herrera-Marschitz M., Meana J.J., O'Connor W.T., Goiny M., Reid M.S., and Ungerstedt U. Neuronal dependence of extracellular dopamine, acetylcholine, glutamate, aspartate and gamma-aminobutyric acid (GABA) measured simultaneously from rat neostriatum using in vivo microdialysis, reciprocal interactions. Amino Acids 2 (1992) 157-179
63. Herrera-Marschitz M., You Z.-B., Goiny M., Meana J.J., Silveira R., Godukhin O., Chen Y., Espinoza S., Pettersson E., Loidl F., Lubec G., Andersson K., Nylander I., Terenius L., and Ungerstedt U. On the origin of extracellular glutamate levels monitored in the basal ganglia by in vivo microdialysis. J. Neurochem. 66 (1996) 1726-1735
64. Herrera-Marschitz M., Goiny M., You Z.-B., Meana J.J., Pettersson E., Rodriguez-Puertas R., Xu Z.-Q., Terenius L., Hökfelt T., and Ungerstedt U. On the release of glutamate and aspartate in the basal ganglia of the rat: interactions with monoamines and neuropeptides. Neurosci. Biobehav. Rev. 21 (1997) 489-495
65. Herrera-Marschitz M., Kohlhauser C., Gomez-Urquijo S., Ubink R., Goiny M., and Hökfelt T. Excitatory amino acids, monoamine and nitric oxide synthase systems in organotypic cultures: biochemical and immunohistochemical analysis. Amino Acids 19 (2000) 33-43
66. Herrera-Marschitz M., Bustamante D., Morales P., and Goiny M. Exploring neurocircuitries of the basal ganglia by intracerebral administration of selective neurotoxins. Neurotoxicity Res. 11 (2007) 169-182
67. Hillered L., Valtysson J., Enblad P., and Persson L. Interstitial glycerol as a marker for membrane phospholipid degradation in the acutely injured human brain. J. Neurol. Neurosurg. Psychiatry 64 (1998) 486-491
68. Hillman J., Milos P., Yu Z.Q., Sjögren F., Anderson C., and Mellergard P. Intracerebral microdialysis in neurosurgical intensive care patients utilising catheters with different molecular cut-off (20 and 100 kD). Acta Neurochir. (Wien) 148 (2006) 319-324
69. Hopkins D.A., and Niessen L.W. Substantia nigra projections to the reticulata formation, superior colliculus and central gray in the rat, cat and monkey. Neurosci. Lett. 2 (1976) 253-259
70. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18 (1966) 925-964
71. Hornykiewicz O. l-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids 23 (2002) 65-70
72. +. Life Sci. 45 (1989) 283-293
73. Hyttel J. SCH 23390-the first selective dopamine D-1 antagonist. Eur. J. Pharmacol. 91 (1983) 153-154
74. Hyttel J. Dopamine D-1 and D-2 receptors. Characterization and differential effects of neuroleptics. Acta Pharm. Suecica Suppl. 1 (1986) 426-439
75. Hökfelt T., and Ungerstedt U. Specificity of 6-hydroxy-dopamine induced degeneration of central monoamine neurons: an electron and fluorescence microscopic study with special reference to intracerebral injection on the nigro-striatal dopamine system. Brain Res. 60 (1973) 269-297
76. Hökfelt T., Mårtensson R., Björklund A., Kleinau S., and Goldstein M. Distributional maps of tyrosine-hydroxylase-immunoreactive neurons in the rat brain. In: Björklund A., and Hökfelt T. (Eds). Handbook of Chemical Neuroanatomy. Vol. 2: Classical Transmitters in the CNS, Part I (1984), Elsevier Science Publ. BV, Amsterdam 277-379
77. Hökfelt T., Skirboll L., Rehfeld J.F., Goldstein M., Markey K., and Dann O. A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing. Neuroscience 5 (1980) 2093-2114
78. Iorio L.C., Barnett A., Leitz F.H., Houser V.P., and Korduba C.A. SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J. Pharmacol. Exp. Ther. 226 (1983) 462-468
79. Janson A.M., Meana J.J., Goiny M., and Herrera-Marschitz M. Chronic nicotine treatment counteracts the decrease in extracellular neostriatal dopamine induced by a unilateral transection at the meso-diencephalic junction in rats: a microdialysis study. Neurosci. Lett. 134 (1992) 88-92
80. Jones D.L., and Mogenson G.J. Nucleus accumbens to globus pallidus GABA projection subserving ambulatory activity. Am. J. Physiol. 238 (1980) 65-69
81. Jonsson G., Hallman H., Mefford I., and Adams R.N. The use of liquid chromatography with electrochemical detection for the determination of adrenaline and other biogenic-monoamines in the CNS. In: Fuxe K., Goldstein M., Hökfelt B., and Hökfelt T. (Eds). Central Adrenaline Neurons (1980), Pergamon Press, Oxford-New York 59-71
82. Kilpatrick I.C., Starr M.S., Flechter A., James T.A., and MacLeod N.K. Evidence for a GABAergic nigrothalamic pathway in the rat. Exp. Brain Res. 40 (1980) 45-54
83. Kilpatrick I.C., Collingridge G.L., and Starr M.S. Evidence for the participation of nigrotectal γ-aminobutyrate-containing neurones in striatal and nigral-derived circling in the rat. Neuroscience 7 (1982) 207-222
84. Kita H., Chang H.T., and Kitai S.T. Pallidal inputs to subthalamus: intracellular analysis. Brain Res. 264 (1983) 255-265
85. Klawitter V., Morales P., Johansson S., Bustamante D., Goiny M., Gross J., Luthman J., and Herrera-Marschitz M. Effect of perinatal asphyxia on cell survival, neuronal phenotype and neurite growth evaluated with organotypic triple cultures. Amino Acids 28 (2005) 149-155
86. Klawitter V., Morales P., Bustamante D., Gomez-Urquijo S., Hökfelt T., and Herrera-Marschitz M. Plasticity of basal ganglia neurocircuitries following perinatal asphyxia: effect of nicotinamide. Exp. Brain Res. 180 (2007) 139-152
87. Kostrzewa R.M., and Jacobowitz D.M. Pharmacological actions of 6-hydroxydopamine. Pharmacol. Rev. 26 (1974) 199-288
88. Kretschmer B.D., Goiny M., and Herrera-Marschitz M. Effect of intracerebral administration of NMDA and AMPA on dopamine and glutamate release in the ventral pallidum on motor behaviour. J. Neurochem. 74 (2000) 2049-2057
89. Langer S.Z. The degeneration contraction of the nictitating membrane in the un-anesthetized cat. J. Pharmacol. Exp. Ther. 151 (1966) 66-72
90. 2 dopamine receptors in brain with subtype-specific antibodies. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 8861-8865
91. Lewis P.R., and Shute C.C.D. The cholinergic limbic system: projections to hippocampal formation, medial cortex, nuclei of the ascending cholinergic reticular system, and the subfornical organ and supra-optic crest. Brain 90 (1967) 521-540
92. Lindavall O., and Björklund A. The organization of the ascending catecholamine neuron systems in the rat brain as revealed by the glyoxylic acid fluorescence method. Acta Physiol. Scand. Suppl. 412 (1974) 1-48
93. Lindefors N., Brodin E., and Ungerstedt U. Microdialysis combined with a sensitive radioimmunoassay: a technique for studying in vivo release of neuropeptides. J. Pharmacol. Meth. 17 (1987) 305-312
94. Ljunberg T., and Ungerstedt U. Sensory inattention produced by 6-hydroxy-dopamine-induced degeneration of ascending dopamine neurons in the brain. Exp. Neurol. 53 (1976) 585-600
95. Loopuijt L.D., and Van Der Kooy D. Organization of the striatum: collateralization of its efferent axons. Brain Res. 348 (1985) 86-99
96. Malmfors T., and Sachs Ch. Degeneration of adrenergic nerves produced by 6-hydroxydopamine. Eur. J. Pharmacol. 3 (1968) 89-92
97. Marshall J.F., and Ungerstedt U. Striatal efferent fibers play a role in maintaining rotational behaviour in the rat. Science 198 (1977) 62-64
98. McGinty J.F., Shi X.D., Schwendt M., Saylor A., and Toda S. Regulation of psychostimulant-induced signalling and gene expression in the striatum. J. Neurochem. 104 (2008) 1440-1449
99. Mogenson G.J., and Nielsen M.A. Evidence that an accumbens to subpallidal GABAergic projection contributes to locomotor activity. Brain Res. Bull. 11 (1983) 309-314
100. Monsma Jr. F.J., Manhan L.C., McVittie L.D., Gerfen C.R., and Sibley D.R. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 6723-6727
101. Morino P., Herrera-Marschitz M., Meana J.J., Ungerstedt U., and Hökfelt T. Immunohistochemical evidence for a crossed cholecystokinin corticostriatal pathway in the rat. Neurosci. Lett. 148 (1992) 133-136
102. Neubig R.R., and Siderovski D.P. Regulators of G-protein signalling as new central nervous system drug targets. Nat. Rev. Drug Discov. 11 (2002) 187-197
103. Nilsson O.G., Brandt L., Ungerstedt U., and Saveland H. Bedside detection of brain ischemia using intracerebral microdialysis: subarachnoid hemorrhage and delayed ischemic deterioration. Neurosurgery 45 (1999) 1176-1184
104. Osborne P.G., O'Connor W.T., Drew K.L., and Ungerstedt U. An in vivo microdialysis characterization of extracellular dopamine and GABA in dorsolateral striatum of awake freely moving and anesthetised rats. J. Neurosci. Methods 34 (1990) 99-105
105. Parent A. Comparative Neurobiology of the Basal Ganglia (1986), John Wiley & Sons, New York
106. Paxinos G., and Watson C. The Brain in Stereotaxic Coordinates. second edition (1986), Academic Press, New York
107. Plenz D., and Kitai S.T. Organotypic cortex-striatum-mesencephalon cultures: the nigrostriatal pathway. Neurosci. Lett. 209 (1996) 177-180
108. Plenz D., and Kitai S.T. Generation of high frequency oscillations in cortical circuits of somatosensory cortex cultures. J. Neurophysiol. 76 (1996) 4001-4005
109. Plenz D., and Kitai S.T. Regulation of the nigrostriatal pathway by metabotropic glutamate receptors during development. J. Neurosci. 18 (1998) 4133-4144
110. Plenz D., and Kitai S.T. A basal ganglia pacemarker formed by the subthalamic nucleus and extend globus pallidus. Nature 400 6745 (1999) 677-682
111. Plenz D., Herrera-Marschitz M., and Kitai S.T. Morphological organization of the globus pallidus-subthalamic nucleus system studied in organotypic cultures. J. Comp. Neurol. 397 (1998) 437-457
112. Pycock C.K., and Marsden C.D. The rotating rodent: a two component system?. Eur. J. Pharmacol. 47 (1978) 167-175
113. Rahman Z., Schwarz J., Gold S., Zachariou V., Wein M.N., Choi K.-H., Kovoor A., Cen C.-K., DiLeone R.J., Schwarz S.C., Selley D.E., Sim-Selley L.J., Barrot M., Luedtke R.R., Self D., Neve R.L., and Lester E.J. RGS9 modulates dopamine signalling in the basal ganglia. Neuron 38 (2003) 941-952
114. Reid, M., 1990. Neuropharmacology circuitries of the basal ganglia studied by in vivo microdialysis. Karolinska Institutet-Thesis, Stockholm, pp. 1-69.
115. Reid M., Herrera-Marschitz M., Hökfelt T., Terenius L., and Ungerstedt U. Differential modulation of striatal dopamine release by intranigral injection of gamma-aminobutyric acid (GABA), dynorphin A and substance P. Eur. J. Pharmacol. 147 (1988) 411-420
116. Reinstrup P., Stahl N., Mellergard P., Uski T., Ungerstedt U., and Nordström C.H. Intracerebral microdialysis in clinical practice: baseline values for chemical markers during wakefulness, anesthesia, and neurosurgery. Neurosurgery 47 (2000) 701-709
117. Reynolds J.N., Hyland B.I., and Wickens J.R. A cellular mechanism of reward-related learning. Nature 413 (2001) 67-70
118. Robertson H.A. Dopamine receptor interactions: some implications for the treatment of Parkinson's disease. TIN 15 (1992) 201-206
119. Romero C.A., Bustamante D.A., Zapata-Torres G., Goiny M., Cassels B., and Herrera-Marschitz M. Neurochemical and behavioural characterization of alkoxyamphetamine derivatives in rats. Neurotoxicity Res. 10 (2006) 11-22
120. Rouzaire-Dubois B., Hammond C., Hamon B., and Ferger J. Pharmacological blockade of the globus pallidus-induced inhibitory response of subthalamic cells in the rat. Brain Res. 200 (1980) 321-329
121. 3H]SCH 23390 binding sites in pars reticulata and pars compacta of the substantia nigra of the rat. Neurosci. Lett. 72 (1986) 265-271
122. Schallert T., Wishaw I.Q., Ramirez V.D., and Teitelbaum P. Compulsive, abnormal walking caused by anticholinergics in akinetic, 6-hydroxydopamine-treated rats. Science 199 (1978) 1461-1463
123. Schultz W. Dopamine neurons and their role in reward mechanisms. Curr. Opin. Neurobiol. 7 (1997) 191-197
124. Schwarcz R., Fuxe K., Agnati L.F., Hökfelt T., and Coyle J.T. Rotational behaviour in rats with unilateral striatal kainic acid lesions: a behavioural model for studies on intact dopamine receptors. Brain Res. 170 (1979) 485-495
125. Schwarcz R., Hökfelt T., Fuxe K., Jonsson G., Goldstein M., and Terenius L. Ibotenic acid-induced neuronal degeneration: a morphological and neurochemical study. Exp. Brain Res. 37 (1979) 199-216
126. Seeman P. Brain dopamine receptors. Pharmacol. Rev. 32 (1981) 229-313
127. Senoh S., Creveling C.R., Udenfriend S., and Witkop B. Chemical, enzymatic and metabolic studies on the mechanism of oxidation of dopamine. J. Am. Chem. Soc. 81 (1959) 6236-6240
128. Sharp T., and Zetterström T. What did we learn from microdialysis?. In: Westerink B.H.C., and Cremers T.I.F.H. (Eds). Handbook of Microdialysis (2007), Elsevier BV, Amsterdam 5-15
129. Shute C.C., and Lewis P.R. Electron microscopy of cholinergic terminals and acetylcholinesterase-containing neurones in the hippocampal formation of the rat. Z. Zellforsch. Mikrosk. Anat. 69 (1966) 334-343
130. Shute C.C., and Lewis P.R. The ascending cholinergic reticular system: neocortical, olfactory and subcortical projections. Brain 90 (1967) 497-520
131. Simola N., Morelli M., and Carta A.R. The 6-hydroxydopamine model of Parkinson's disease. Neurotoxicity Res. 11 (2007) 151-187
132. Skjoth-Rasmussen J., Schulz M., Kristensen S.R., and Bjerre P. Delayed neurological deficits detected by an ischemic pattern in the extracellular cerebral metabolites in patients with aneurysmal subarachnoid hemorrhage. J. Neurosurg. 100 (2004) 8-15
133. Taymans J.-M., Kia H.K., Claes R., Cruz C., Leysen J., and Langlois X. Dopamine receptor-mediated regulation of RGS2 and RGS4 mRNA differentially depends on ascending dopamine projections and time. Eur. J. Neurosci. 19 (2004) 2249-2260
134. Tekumalla P.K., Calon F., Rahman Z., Birdi S., Rajput A.H., Hornykiewicz O., Di-Paolo T., Bedard P.J., and Nestler E.J. Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease. Biol. Psychiatry 50 (2001) 813-816
135. Thomas E.A., Danielson P.E., and Sutcliffe J.G. RGS9: a regulator of G-protein signalling with specific expression in rat and mouse striatum. J. Neurosci. Res. 52 (1998) 118-124
136. Tillerson J.L., Cohen A.D., Philhower J., Miller G.W., Zigmond M.J., and Schallert T. Forced limb-use effects on the behavioural and neurochemical effects of 6-hydroxydopamine. J. Neurosci. 21 (2001) 4427-4435
137. Trabucchi M., Longoni R., Fresia S., and Spano P.F. Sulpiride: a study of the effects on dopamine receptors in rat neostriatum and limbic forebrain. Life Sci. 17 (1975) 1551
138. Tranzer J.P., and Thoenen H. Ultramorphologische Veränderungen der sympatschen Nervändigungen der Katze nach Vorbehandlung mit 5- und 6-hydroxy-Dopamine. Naunyn-Schmiedeberg's Arch. Exp. Path. Pharmak. 257 (1967) 343-344
139. Tranzer J.P., and Thoenen H. An electron microscopic study of selective, acute degeneration of sympathetic nerve terminals after administration of 6-hydroxydopamine. Experientia 24 (1968) 155-156
140. Traynor J.R., and Neubig R.R. Regulators of protein signalling and drugs of abuse. Mol. Interv. 5 (2005) 30-41
141. Udesen A., Lontoft E., and Kristensen S.R. Monitoring of free TRAM flaps with microdialysis. J. Reconstr. Microsurg. 16 (2000) 101-106
142. Ungerstedt U. 6-Hydroxydopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5 (1968) 107-110
143. Ungerstedt U. Stereotaxic mapping of the monoamine pathway in the rat brain. Acta Physiol. Scand. Suppl. 367 (1971) 1-48
144. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 367 (1971) 69-93
145. Ungerstedt U. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol. Scand. Suppl. 367 (1971) 49-68
146. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 367 (1971) 95-122
147. Ungerstedt U. 6-Hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome. Pharmacol. Ther. Behav. 2 (1976) 37-40
148. Ungerstedt U. Microdialysis-principles and applications for studies in animals and man. J. Intern. Med. 230 (1991) 365-373
149. Ungerstedt U., and Arbuthnott G.W. Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 24 (1970) 485-493
150. Ungerstedt U., and Pycock C. Functional correlates of dopamine neurotransmission. Bull. Schweiz. Acad. Med. Wiss. 1278 (1974) 1-5
151. Ungerstedt U., Marshall J.F., Jonsson G., Malmfors T., and Sachs Ch. Nerve degeneration in functional studies: experiments illustrating the problem of lesion specificity and compensatory supersensitivity. In: Malmfors T., and Thoenen H. (Eds). Chemical Tools in Catecholamine Research (1975), North-Holland Pub. Co., Amsterdam 311-318
152. Ungerstedt U., and Herrera-Marschitz M. Behavioural pharmacology of dopamine receptor mechanisms. In: Stjärne L., Hedqvist P., Lagercrantz H., and Wennmalm A. (Eds). Chemical Neurotransmission 75 Years (1981), Academic Press, New York 481-494
153. Ungerstedt U., Herrera-Marschitz M., Jungnelius U., Ståhle L., Tossman U., and Zetterström T. Dopamine synaptic mechanisms reflected in studies combining behavioural recordings and brain dialysis. Adv. Biosci. 37 (1982) 219-231
154. Van Der Kooy D., Hattori T., Shannak K., and Hornykiewicz O. The pallido-subthalamic projection in rat: anatomical and biochemical studies. Brain Res. 204 (1981) 253-268
155. Vincent S.R., Hattori T., and McGeer E.G. The nigro-tectal projection: a biochemical and ultrastructural characterization. Brain Res. 151 (1978) 159-164
156. Westerink B.H.C., Hofsteed H.M., Damsma G., and de Vries G.B. The significance of extracellular calcium for the release of dopamine, acetylcholine and amino acids in conscious rats evaluated by brain microdialysis. Naunyn-Schmiedeberg's Arch. Pharmacol. 337 (1988) 373-378
157. Wickens J.R., Begg A.J., and Arbuthnott G.W. Dopamine reverses the depression of rat corticostriatal synapses which normally follows high-frequency stimulation of cortex in vitro. Neuroscience 70 (1996) 1-6
158. Woodland C., Huang T.T., Gryz E., Bendayan R., and Fawcett J.P. Expression, activity and regulation of CYP3A in human and rodent brain. Drug Metab. Rev. 40 (2008) 149-168
159. You Z.-B., Herrera-Marschitz M., Brodin E., Meana J.J., Morino P., Hökfelt T., Silveira R., Goiny M., and Ungerstedt U. On the origin of striatal cholecystokinin release: studies with in vivo microdialysis. J. Neurochem. 62 (1994) 76-85
160. +-depolarization, lesions and peptidase inhibition. Neuroscience 63 (1994) 415-425
161. 2 receptor agonists. Neuroscience 63 (1994) 427-434
162. Zetterström, T., 1986. Pharmacological analysis of central dopaminergic neurotransmission using a novel in vivo brain perfusion method. Karolinska Institutet-Thesis, Stockholm, pp. 1-45.
163. Zetterström T., Sharp T., Marsden C.A., and Ungerstedt U. In vivo measurement of dopamine and its metabolites studied by intracerebral dialysis: changes after d-amphetamine. J. Neurochem. 41 (1983) 1769-1773
164. Zetterström T., Herrera-Marschitz M., and Ungerstedt U. Simultaneous measurement of dopamine release and rotational behaviour in 6-hydroxydopamine denervated rats using intracerebral dialysis. Brain Res. 376 (1986) 1-7
165. Zhan K., Howes K.A., He W., Bronson J.D., Pettenati M.J., Chen C.-K., Palczewski K., Wensel T.G., and Baehr W. Structure, alternative splicing, and expression of the human RGS9 gene. Gene 240 (1999) 23-34
166. Zhou Q.J., Grandy D.K., Thambi L., Kushner J.A., Van Tol H.H.M., Cone R., Pribnow D., Salon J., Bunzow J.R., and Civelli O. Cloning and expression of human and rat D1 dopamine receptors. Nature 347 (1990) 76-80